Quick Answer
Intellia Therapeutics, Inc. reported R&D Expense of $388.86 million for fiscal year 2025.
Intellia Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $388.86M | -16.6% |
| 2024 | $466.31M | +7.2% |
| 2023 | $435.07M | +3.6% |
| 2022 | $419.98M | +82.8% |
| 2021 | $229.81M | +52.8% |
| 2020 | $150.41M | +38.7% |
| 2019 | $108.41M | +21.7% |
| 2018 | $89.11M | +31.7% |
| 2017 | $67.65M | +112.5% |
| 2016 | $31.84M | +185.0% |
| 2015 | $11.17M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $94.75M | -23.2% | -2.4% |
| June 30, 2025 | $97.03M | -15.0% | -10.5% |
| March 31, 2025 | $108.43M | -3.1% | -12.1% |
| September 30, 2024 | $123.38M | +8.5% | +8.0% |
| June 30, 2024 | $114.21M | -0.9% | +2.1% |
| March 31, 2024 | $111.85M | +15.2% | -1.6% |
| September 30, 2023 | $113.70M | +17.6% | -1.4% |
| June 30, 2023 | $115.28M | +27.8% | +18.7% |
- Intellia Therapeutics, Inc. showed a decrease of -16.6% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Intellia Therapeutics, Inc.’s r&d expense has grown by 3381.3% (from $11.17 million to $388.86 million).
- The most recent figure is from Intellia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: